Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials
Gespeichert in:
| Veröffentlicht in: | Hematological oncology 2023-06, Vol.41 (S2), p.461-463 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 463 |
|---|---|
| container_issue | S2 |
| container_start_page | 461 |
| container_title | Hematological oncology |
| container_volume | 41 |
| creator | Tedeschi, A. Ahn, I. E. Fraser, G. A. M. Greil, R. Munir, T. Kay, N. E. Flinn, I. W. Lee, S. Saifan, C. Kearbey, J. Patel, S. Barrientos, J. C. |
| description | |
| doi_str_mv | 10.1002/hon.3164_340 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3089984255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089984255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1924-89ea4082c0c7b5a842a91c45d10db876a43e5cd40dd689cb7302412e66c64eac3</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhS0EEpfSHQ8wEhuQmjJ2nB-zQ1VLK1UtC7q2HHvCdUnii53bKu_Dg-L0lm1X54zmm6ORDmMfOJ5yRPFlG6bTktdSlxJfsQ1HpQqOtXrNNiiatkBRirfsXUr3iHmH7Yb9verifvaT7-BTtp_BhUQwBud7b83swwR9iDCayfyikaYZQg9k4rCANdF5Y8G4B4r5iB7yOoGfYJcPn_yjn7dgtzFM3sKwjLttsMu8etr_ptGbr_AjhIEc5PxhST6t8Q3YIX9kzQBz9GZI79mbPgsdP-sRu7s4_3l2WVzffr86-3ZdWK6ELFpFRmIrLNqmq0wrhVHcyspxdF3b1EaWVFkn0bm6VbZrShSSC6prW0sytjxiHw-5uxj-7CnN-j7sY_4s6RJbpXJiVWXq5EDZGFKK1Otd9KOJi-ao1x507kH_7yHj1QF_9AMtL7L68vZmlXUu_wHlIY6h</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089984255</pqid></control><display><type>article</type><title>Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Tedeschi, A. ; Ahn, I. E. ; Fraser, G. A. M. ; Greil, R. ; Munir, T. ; Kay, N. E. ; Flinn, I. W. ; Lee, S. ; Saifan, C. ; Kearbey, J. ; Patel, S. ; Barrientos, J. C.</creator><creatorcontrib>Tedeschi, A. ; Ahn, I. E. ; Fraser, G. A. M. ; Greil, R. ; Munir, T. ; Kay, N. E. ; Flinn, I. W. ; Lee, S. ; Saifan, C. ; Kearbey, J. ; Patel, S. ; Barrientos, J. C.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3164_340</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Chronic lymphocytic leukemia ; Clinical trials ; Inhibitor drugs ; Leukemia ; Lymphatic leukemia ; Targeted cancer therapy</subject><ispartof>Hematological oncology, 2023-06, Vol.41 (S2), p.461-463</ispartof><rights>2023 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1924-89ea4082c0c7b5a842a91c45d10db876a43e5cd40dd689cb7302412e66c64eac3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhon.3164_340$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhon.3164_340$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Tedeschi, A.</creatorcontrib><creatorcontrib>Ahn, I. E.</creatorcontrib><creatorcontrib>Fraser, G. A. M.</creatorcontrib><creatorcontrib>Greil, R.</creatorcontrib><creatorcontrib>Munir, T.</creatorcontrib><creatorcontrib>Kay, N. E.</creatorcontrib><creatorcontrib>Flinn, I. W.</creatorcontrib><creatorcontrib>Lee, S.</creatorcontrib><creatorcontrib>Saifan, C.</creatorcontrib><creatorcontrib>Kearbey, J.</creatorcontrib><creatorcontrib>Patel, S.</creatorcontrib><creatorcontrib>Barrientos, J. C.</creatorcontrib><title>Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials</title><title>Hematological oncology</title><subject>Chronic lymphocytic leukemia</subject><subject>Clinical trials</subject><subject>Inhibitor drugs</subject><subject>Leukemia</subject><subject>Lymphatic leukemia</subject><subject>Targeted cancer therapy</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1TAQhS0EEpfSHQ8wEhuQmjJ2nB-zQ1VLK1UtC7q2HHvCdUnii53bKu_Dg-L0lm1X54zmm6ORDmMfOJ5yRPFlG6bTktdSlxJfsQ1HpQqOtXrNNiiatkBRirfsXUr3iHmH7Yb9verifvaT7-BTtp_BhUQwBud7b83swwR9iDCayfyikaYZQg9k4rCANdF5Y8G4B4r5iB7yOoGfYJcPn_yjn7dgtzFM3sKwjLttsMu8etr_ptGbr_AjhIEc5PxhST6t8Q3YIX9kzQBz9GZI79mbPgsdP-sRu7s4_3l2WVzffr86-3ZdWK6ELFpFRmIrLNqmq0wrhVHcyspxdF3b1EaWVFkn0bm6VbZrShSSC6prW0sytjxiHw-5uxj-7CnN-j7sY_4s6RJbpXJiVWXq5EDZGFKK1Otd9KOJi-ao1x507kH_7yHj1QF_9AMtL7L68vZmlXUu_wHlIY6h</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Tedeschi, A.</creator><creator>Ahn, I. E.</creator><creator>Fraser, G. A. M.</creator><creator>Greil, R.</creator><creator>Munir, T.</creator><creator>Kay, N. E.</creator><creator>Flinn, I. W.</creator><creator>Lee, S.</creator><creator>Saifan, C.</creator><creator>Kearbey, J.</creator><creator>Patel, S.</creator><creator>Barrientos, J. C.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202306</creationdate><title>Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials</title><author>Tedeschi, A. ; Ahn, I. E. ; Fraser, G. A. M. ; Greil, R. ; Munir, T. ; Kay, N. E. ; Flinn, I. W. ; Lee, S. ; Saifan, C. ; Kearbey, J. ; Patel, S. ; Barrientos, J. C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1924-89ea4082c0c7b5a842a91c45d10db876a43e5cd40dd689cb7302412e66c64eac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Chronic lymphocytic leukemia</topic><topic>Clinical trials</topic><topic>Inhibitor drugs</topic><topic>Leukemia</topic><topic>Lymphatic leukemia</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tedeschi, A.</creatorcontrib><creatorcontrib>Ahn, I. E.</creatorcontrib><creatorcontrib>Fraser, G. A. M.</creatorcontrib><creatorcontrib>Greil, R.</creatorcontrib><creatorcontrib>Munir, T.</creatorcontrib><creatorcontrib>Kay, N. E.</creatorcontrib><creatorcontrib>Flinn, I. W.</creatorcontrib><creatorcontrib>Lee, S.</creatorcontrib><creatorcontrib>Saifan, C.</creatorcontrib><creatorcontrib>Kearbey, J.</creatorcontrib><creatorcontrib>Patel, S.</creatorcontrib><creatorcontrib>Barrientos, J. C.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tedeschi, A.</au><au>Ahn, I. E.</au><au>Fraser, G. A. M.</au><au>Greil, R.</au><au>Munir, T.</au><au>Kay, N. E.</au><au>Flinn, I. W.</au><au>Lee, S.</au><au>Saifan, C.</au><au>Kearbey, J.</au><au>Patel, S.</au><au>Barrientos, J. C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials</atitle><jtitle>Hematological oncology</jtitle><date>2023-06</date><risdate>2023</risdate><volume>41</volume><issue>S2</issue><spage>461</spage><epage>463</epage><pages>461-463</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.3164_340</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2023-06, Vol.41 (S2), p.461-463 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_3089984255 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Chronic lymphocytic leukemia Clinical trials Inhibitor drugs Leukemia Lymphatic leukemia Targeted cancer therapy |
| title | Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibrutinib%20(Ibr)%20dose%20modification%20for%20management%20of%20early%20cardiac%20adverse%20events%20in%20patients%20with%20chronic%20lymphocytic%20leukemia:%20Pooled%20analysis%20of%207%20clinical%20trials&rft.jtitle=Hematological%20oncology&rft.au=Tedeschi,%20A.&rft.date=2023-06&rft.volume=41&rft.issue=S2&rft.spage=461&rft.epage=463&rft.pages=461-463&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3164_340&rft_dat=%3Cproquest_cross%3E3089984255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089984255&rft_id=info:pmid/&rfr_iscdi=true |